Sanara MedTech (NASDAQ:SMTI – Get Free Report) had its price target cut by stock analysts at Cantor Fitzgerald from $59.00 to $49.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 43.70% from the stock’s current price.
Separately, TheStreet cut Sanara MedTech from a “c-” rating to a “d+” rating in a research note on Friday, October 20th.
Sanara MedTech Stock Up 19.4 %
Sanara MedTech (NASDAQ:SMTI – Get Free Report) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $15.75 million during the quarter. Sanara MedTech had a negative net margin of 13.05% and a negative return on equity of 20.84%. On average, equities analysts anticipate that Sanara MedTech will post -0.31 EPS for the current year.
Hedge Funds Weigh In On Sanara MedTech
Several hedge funds have recently made changes to their positions in SMTI. Lazard Asset Management LLC acquired a new stake in shares of Sanara MedTech in the third quarter valued at approximately $78,000. Tower Research Capital LLC TRC lifted its position in Sanara MedTech by 363.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 797 shares of the company’s stock worth $25,000 after acquiring an additional 625 shares during the period. Strs Ohio lifted its position in Sanara MedTech by 112.5% during the 3rd quarter. Strs Ohio now owns 1,700 shares of the company’s stock worth $52,000 after acquiring an additional 900 shares during the period. Barclays PLC purchased a new position in shares of Sanara MedTech in the 2nd quarter valued at approximately $30,000. Finally, California State Teachers Retirement System acquired a new position in shares of Sanara MedTech in the second quarter valued at approximately $51,000. Hedge funds and other institutional investors own 7.83% of the company’s stock.
Sanara MedTech Company Profile
Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.
- Five stocks we like better than Sanara MedTech
- What is a SEC Filing?
- 3 intriguing late-week earnings plays for short-term traders
- Consumer Staples Stocks, Explained
- Datadog is about to hit 52-week highs, and there’s more to come
- Trading Halts Explained
- Left for dead, Tower Semiconductor is a phoenix rising
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.